

NAMSDL



National Alliance for Model State Drug Laws

BILL STATUS – CARRYOVER, 2012 AND SPECIAL SESSIONS CATHINONE DERIVATIVES

© 2012 Research is current as of March 9, 2012. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

<u>State</u>	<u>Bill No.</u>	<u>Brief Description</u>	<u>Status</u>	<u>Date of Last Action</u>
Alabama	H.B. 158	adds methylone, MDPV, mephedrone, methedrone, 3-FMC, 4-FMC	Read 1 st time and referred to Senate committee	2/28/2012
Alabama	S.B. 208	adds methylone, MDPV, mephedrone, methedrone, 3-FMC, 4-FMC	Passed Senate; in House committee	2/23/2012
Alaska	S.B. 140	adds MDPV, mephedrone, generic language	Passed Senate; referred to House	3/6/2012
Alaska	H.B. 253	adds MDPV, mephedrone, generic language	Referred to committee	2/10/2012
Arizona	S.B. 1043	adds fluoromethcathinone, butylone, MDPV, methylmethcathinone, methoxymethcathinone, NRG-1, methylone	Passed Senate; referred to House	1/19/2012
Arizona	H.B. 2356	adds fluoromethcathinone, butylone, MDPV, methylmethcathinone, methoxymethcathinone, NRG-1, methylone	Signed by Governor	2/17/2012
Colorado	S.B. 116	adds metamfepramone, ethcathinone, a-PPP, buphedrone, a-PBP, a-PVP, mephedrone, MaPPP, MPBP, methedrone, MOPPP, fluoromethcathinone, methylone, MDPPP, MDPV, NRG-1	Third reading; passed	3/9/2012
D.C.	L.B. B19-645	adds BZP, ephedrone, MDPV, mephedrone	Hearing set for 3/16/2012	1/13/2012
D.C.	L.B. B19-631	adds MDPV, mephedrone, methylone, methedrone, 3-fluoromethcathinone, 4-fluoromethcathinone	Hearing set for 3/16/2012	12/30/2011
Delaware	S.B. 160	adds 3-fluoromethcathinone, 4-fluoromethcathinone, a-PPP, a-PVP, BZ-6378, butylone, ephedrone, ethcathinone, ethylone, MDPPP, MDPV, mephedrone, metamfepramone, methedrone, methylone, MOPPP, MPBP, NRG-1	Signed by Governor	1/25/2012
Florida	H.B. 1175	adds buphedrone, butylone, BZP, ethcathinone, ethylone, eutylone, MDPBP, MDPPP, MOPPP, NRG-1, pentylone, a-PBP, a-PVP, a-PPP, MaPPP	Passed Senate as amended; House concurred in 1 amdmt, refused to concur in 1	3/7/2012

© 2012 Research is current as of March 9, 2012. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

			amdmnt.; in Senate returning messages	
Florida	S.B. 1502	adds buphedrone, butylone, BZP, ethcathinone, ethylone, eutylone, MDPBP, MDPPP, MOPPP, NRG-1, pentylone, a-PBP, a-PVP, a-PPP, MaPPP	Substituted by H.B. 1175; laid on table	3/6/2012
Georgia	S.B. 445	Adds BZP, 4-fluoromethcathinone, methylone, mephedrone, methedrone, MDPV	Senate withdrawn bill/res consideration	2/28/2012
Hawaii	H.B. 2600	adds mephedrone, MDPV, methylone, generic language	Passed House; in Senate committee	3/8/2012
Illinois	H.B. 5233	Adds pentedrone	Passed House; placed on calendar order of 1st reading	3/7/2012
Indiana	S.B. 26	adds fluoromethcathinone, 4-EMC, MDPV, mephedrone, methedrone, methylone	Conference committee report adopted by Senate and House	3/8/2012
Indiana	H.B. 1196	adds MPBP, a-PPP, a-PVP, buphedrone, butylone, 2-DPMP, ethylone, eutylone, 4-fluoromethcathinone, MDAI, NRG-1, pentedrone, pentylone, generic language	House concurred in Senate amendments; technical correction adopted by Senate	3/8/2012
Indiana	S.B. 234	adds MPBP, MDPV, a-PPP, a-PVP, buphedrone, butylone, 2-DPMP, ethylone, eutylone, 4-fluoromethcathinone, MDAI, NRG-1, pentedrone, pentylone, generic language	Senate dissented from amendments; conferees and advisors appointed	3/8/2012
Iowa	H.S.B. SB609	adds mephedrone, MDPV, methylone, NRG-1, methedrone, ethcathinone, ethylone, butylone, metamfepramone, a-PPP, MOPPP, MDPPP, a-PVP, MDAI, 3-FMC, 4-FMC, MPBP	Voted – Public Safety	2/23/2012
Iowa	S.S.B. SB3104	adds mephedrone, MDPV, methylone, NRG-1, methedrone, ethcathinone,	Filed	1/30/2012

© 2012 Research is current as of March 9, 2012. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

		ethylone, butylone, metamfepramone, a-PPP, MOPPP, MDPPP, a-PVP, MDAI, 3-FMC, 4-FMC, MPBP		
Iowa	H.F. 2398	Adds mephedrone, MDPV, methylone, NRG-1, 4-fluoromethcathinone, methedrone, ethcathinone, ethylone, butylone, metamfepramone, a-PPP, MOPPP, MDPPP, a-PVP, MDAI, 3-fluoromethcathinone, MPBP	Introduced; placed on calendar	2/28/2012
Kentucky	H.B. 176	adds buphedrone, BZP, ethcathinone, generic language	Referred to committee	1/4/2012
Kentucky	H.B. 185	adds buphedrone, BZP, ethcathinone, generic language	Referred to committee	1/4/2012
Kentucky	S.B. 173	Adds buphedrone, ethcathinone, BZP, generic language	Introduced	2/24/2012
Kentucky	S.B. 188	adds buphedrone, BZP, ethcathinone, generic language	Referred to committee	3/5/2012
Kentucky	H.B. 481	adds buphedrone, BZP, ethcathinone, generic language	Posted for passage	3/7/2012
Maryland	H.B. 589	adds methylone, MDPV, mephedrone, methedrone, 4-fluoromethcathinone, 3-fluoromethcathinone	Hearing set for 3/6 at 1pm	2/10/2012
Massachusetts	S.B. 2122	adds methylone, MDPV, mephedrone, methedrone, 3-fluoromethcathinone, 4-fluoromethcathinone, NRG-1, butylone, methcathinone, HMMC, MPBP, ephedrone, 4-EMC, 3,4-DMMC, a-PVP, eutylone, ethylone	Passed as amended; ordered engrossed in Senate	2/2/2012
Massachusetts	S.B. 2125	adds methylone, MDPV, mephedrone, methedrone, 3-fluoromethcathinone, 4-fluoromethcathinone, NRG-1, butylone, methcathinone, HMMC, MPBP, ephedrone, 4-EMC, 3,4-DMMC, a-PVP, eutylone, ethylone	Passed Senate; referred to House	2/6/2012
Michigan	H.B. 5250	adds 4-fluoromethcathinone, methylone	Printed bill filed	1/18/2012
Minnesota	H.F. 2508	Adds MDAI, BZP, mephedrone, methedrone, MDPV, fluoromethcathinone, buphedrone, butylone, BZ-6378, NRG-1, generic language	Committee report do pass; re-referred to committee	3/5/2012
Minnesota	S.F. 2319	Adds MDAI, BZP, mephedrone, methedrone, MDPV, fluoromethcathinone, buphedrone, butylone, BZ-6378, NRG-1, generic language	Introduced and referred to committee	3/8/2012
Nebraska	L.B. 814	adds fluoromethcathinone, butylone,	Placed on	2/2/2012

© 2012 Research is current as of March 9, 2012. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

		MDPV, mephedrone, methedrone, methylone, NRG-1, generic language	general file	
New Mexico	H.B. 93	adds a-PPP, a-PVP, butylone, ethcathinone, ethylone, MDAI, MDPPP, metamfepramone, MOPPP, NRG-1	Introduced	1/18/2012
Ohio	S.B. 301	Adds methylone, MDPV, mephedrone, methedrone, 3-fluoromethcathinone, 4-fluoromethcathinone	Introduced	2/15/2012
Ohio	H.B. 467	Adds methylone, MDPV, mephedrone, methedrone, 3-FMC, 4-FMC	Introduced	2/28/2012
Rhode Island	S.B. 2154	adds fluoromethcathinone, MDPV, mephedrone, methoxymethcathinone, methylone	Introduced; referred to committee	1/18/2012
Rhode Island	H.B. 7170	adds fluoromethcathinone, MDPV, mephedrone, methoxymethcathinone, methylone	Committee recommends measure be held for further study	2/8/2012
Rhode Island	S.B. 2501	Adds methylone, MDPV, mephedrone, methoxymethcathinone, fluoromethcathinone	Introduced; referred to committee	2/16/2012
Rhode Island	H.B. 7574	Adds methylone, MDPV, mephedrone, methoxymethcathinone, fluoromethcathinone	Introduced; referred to committee	2/15/2012
South Carolina	S.B. 1056	adds 4-fluoromethcathinone, 4-MEC, buphedrone, butylone, MDPV, mephedrone, methedrone, methylone, pentedrone, pentylone, generic language	Passed Senate; referred to House committee	2/7/2012
South Carolina	H.B. 3793	adds 4-fluoromethcathinone, 4-MEC, buphedrone, butylone, MDPV, mephedrone, methedrone, methylone, pentedrone, pentylone, generic language	Read third time; returned to House with amendments	3/7/2012
South Carolina	S.B. 1005	adds 3-fluoromethcathinone, 4-fluoromethcathinone, butylone, MDPV, mephedrone, methedrone, methylone, NRG-1	Referred to subcommittee	1/9/2012
South Carolina	H.B. 4471	adds generic language	Referred to committee	1/10/2012
South Carolina	H.B. 4515	adds generic language	Referred to committee	1/10/2012
South Dakota	S.B. 23	adds 3-fluoromethcathinone, 4-fluoromethcathinone, a-PPP, a-PVP, butylone, ethcathinone, ethylone, MDPPP, MDPV, mephedrone, metamfepramone, methedrone, methylone, MOPPP, MPBP,	Signed by Governor	2/24/2012

© 2012 Research is current as of March 9, 2012. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

		NRG-1, generic language		
Tennessee	S.B. 2507	adds methylone, MDPV, mephedrone, methedrone, HMMC, flephedrone, 3-FMC, MPBP, ephedrone, 4-EMC, 3,4-DMMC, a-PVP, NRG-1, butylone, pentylone, eutylone, ethylone, generic language	Referred to committee	1/19/2012
Tennessee	H.B. 2645	adds methylone, MDPV, mephedrone, methedrone, HMMC, flephedrone, 3-FMC, MPBP, ephedrone, 4-EMC, 3,4-DMMC, a-PVP, NRG-1, butylone, pentylone, eutylone, ethylone, generic language	Recommend pass if amended; referred to committee	3/7/2012
Tennessee	S.B. 2804	adds 3-fluoromethcathinone, 4-fluoromethcathinone, MDPV, mephedrone, methedrone, methylone	Referred to committee	1/26/2012
Tennessee	H.B. 2925	adds 3-fluoromethcathinone, 4-fluoromethcathinone, MDPV, mephedrone, methedrone, methylone	Assigned to subcommittee	2/8/2012
Tennessee	S.B. 2230	adds BZP	Received from Senate; held on House desk	2/16/2012
Tennessee	H.B. 2368	adds BZP	Recommended for passage; referred to committee	3/7/2012
Utah	H.B. 254	adds fluoromethcathinone, BZP	Passed House and Senate as amended; signed by Speaker and President	3/8/2012
Virginia	H.B. 986	adds 3,4-DMMC, 3-fluoromethcathinone, 4-fluoromethcathinone, 4-EMC, 4-MEC, a-PPP, a-PVP, buphedrone, butylone, ethcathinone, ethylone, MDAI, MDPPP, metamfepramone, methedrone, methylone, MOPPP, MaPPP, NRG-1, pentedrone, pentylone	Left in Courts of Justice	2/14/2012
Virginia	S.B. 273	adds 3,4-DMMC, 3-fluoromethcathinone, 4-fluoromethcathinone, 4-EMC, 4-MEC, a-PPP, a-PVP, buphedrone, butylone, ethcathinone, ethylone, MDAI, MDPPP, metamfepramone, methedrone, methylone, MOPPP, MaPPP, NRG-1, pentedrone, pentylone	Passed House; enrolled	3/8/2012
Virginia	S.B. 223	adds 3,4-DMMC, 3-fluoromethcathinone,	Incorporated	1/23/2012

© 2012 Research is current as of March 9, 2012. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

		4-fluoromethcathinone, 4-EMC, 4-MEC, a-PPP, a-PVP, buphedrone, butylone, ethcathinone, ethylone, MDAI, MDPPP, metamfepramone, methedrone, methylone, MOPPP, MaPPP, NRG-1, pentedrone, pentylone	into SB273	
Virginia	H.B. 508	adds 3,4-DMMC, 3-fluoromethcathinone, 4-fluoromethcathinone, 4-EMC, 4-MEC, a-PPP, a-PVP, buphedrone, butylone, ethcathinone, ethylone, MDAI, MDPPP, metamfepramone, methedrone, methylone, MOPPP, MaPPP, NRG-1, pentedrone, pentylone	Passed Senate and House; signed by Speaker and President	3/8/2012
Washington	S.B. 6007	adds generic language	Referred to committee	1/9/2012
United States	S409	adds mephedrone and MDPV	Placed on Senate calendar	7/28/2011
United States	HR1571	adds mephedrone and MDPV	Referred to committee	7/11/2011
United States	HR1254	adds 3-fluoromethcathinone, 4-fluoromethcathinone, a-PPP, a-PVP, butylone, ethcathinone, ethylone, MDAI, MDPPP, MDPV, mephedrone, metamfepramone, methedrone, methylone, MOPPP, MPBP, NRG-1	Passed House; referred to Senate committee	12/8/2011

© 2012 Research is current as of March 9, 2012. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.